Senseonics Price Target Raised to $1.40 from $1.10 by H.C. Wainwright.

H.C. Wainwright has raised the price target for Senseonics (SENS) to $1.40 from $1.10 and maintains a Buy rating. The firm believes Senseonics can reach operational break-even by the end of 2027, driven by plans to increase Eversense patients from 13,000 in 2025 to over 50,000 by 2027.

H.C. Wainwright has raised its price target for Senseonics Holdings (NYSE: SENS) to $1.40 from $1.10, while maintaining a Buy rating. The research firm believes that Senseonics can reach operational break-even by the end of 2027, driven by plans to significantly increase its Eversense patient base from approximately 13,000 in 2025 to over 50,000 by 2027 [1].

Key growth drivers identified by H.C. Wainwright include the approval and launch of Eversense 365 in the EU, expected in the second half of 2025; the launch of Eversense pairing with Sequel Diabetes twiist insulin delivery system also in the second half of 2025; the launch of the Gemini system in the second half of 2026; and the launch of the Freedom system in 2027. These launches are anticipated to drive significant revenue growth, with the firm forecasting total revenues of $75.6 million in 2026 and $118.4 million in 2027 [1].

Senseonics reported mixed financial results for the first quarter of 2025, achieving an earnings per share of -$0.02, which was better than the expected -$0.03, but fell short of revenue forecasts. Despite this, the company demonstrated a 24% year-over-year growth in net revenue. Additionally, Senseonics reduced its debt to $35.3 million, strengthening its financial position [1].

In a strategic move, Senseonics initiated a public stock offering and a private placement, with Abbott Laboratories (NYSE: ABT) agreeing to purchase up to $25 million in common stock. The proceeds are earmarked for launching Eversense 365 and other corporate purposes [1].

References:

[1] https://www.investing.com/news/analyst-ratings/hc-wainwright-raises-senseonics-stock-price-target-to-140-on-growth-outlook-93CH-4126254